You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202361 - 202370 of 207700 results
  1. Validation of New Mass Spectrometric Blood Folate Assay

    SBC: Smd, Inc.            Topic: N/A

    N/A

    SBIR Phase I 1995 Department of Health and Human Services
  2. Validation of Next-Generation Weapons Platforms Components with High Frequency, Hardware-In-The-Loop Motion Simulation

    SBC: ETEGENT TECHNOLOGIES, LTD.            Topic: AF203CSO1

    Development programs for next-generation missiles, precision guided munitions and hypersonic platforms require system component operation be validated in hardware-in-the-loop (HWIL) test systems which can deterministically replicate the harsh, high frequency, multi-degree-of-freedom (MDOF) vibration environment experienced in flight. Such test systems do not  currently exist. Etegent proposes to ...

    SBIR Phase I 2021 Department of DefenseAir Force
  3. Validation of novel parallel hematopoietic cell sorter

    SBC: Cellerant Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Hematopoietic cell transplantation is a component of standard therapy for many malignant hematological diseases and is actively being investigated for use in treating non-hematological malignancies and autoimmune diseases, preventing the rejection of solid organ transplants and delivering gene therapy and immune therapy. The use of highly purified hematopoietic ...

    SBIR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  4. Validation of Novel Therapeutic Approach for Cryptococcal Meningitis

    SBC: Minnetronix Medical, Inc.            Topic: NIAID

    Validation of a Novel Therapeutic Approach for Cryptococcal Meningitis PILadShivanand and McCabeAaron Project Summary When Cryptococcus is manifested as cryptococcal meningitisCMit creates a large burden of mortality and morbidity to the patient and is very difficult for the clinician to treatThere are now an estimatedUS cases andcases of CM worldwide annuallywith estimated mortality ofper yearCM ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Validation of Novel Therapeutic Approach for Leptomeningeal Metastases

    SBC: Minnetronix Medical, Inc.            Topic: 102

    ABSTRACT Leptomeningeal Metastases (LM) is a condition in which tumor cells from a primary tumor metastasize, invade the subarachnoid space (SAS) and spread throughout the cerebrospinal fluid (CSF), resulting in seeding along the meninges, brain and spinal cord. LM represents a devastating event of cancer progression. There are 30,000 cases annually and currently no cure, with average survival of ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Validation of Organotypic Vaginal Tissue Based Assay for Endocrine Disruptors

    SBC: Mattek Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Environmental or intentional exposure to a broad variety of chemical agents can alter normal endocrine function. The effects of these "endocrine disruptors" (ED) can have serious health implications including deleterious effects to reproductive capacity, fetal development, the immune system, and carcinogenesis. Current animal tests are expensive, use a large nu ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  7. Validation of packed Red Blood Cell Mechanical Fragility to Indicate Transfusion Outcomes

    SBC: Blaze Medical Devices            Topic: NHLBI

    DESCRIPTION provided by applicant Blaze Medical Devices Blaze is dedicated to improving the safety and the efficacy of the nationandapos s blood supply Blaze is developing a test to quantify the prospective efficacy of each Red Blood Cell RBC unit The need for such testing is predicated upon the adverse effects and unpredictable efficacy of transfused RBC due to inter donor variability d ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Validation of Platelet Expression of FcɣRIIa as a Precision Tool

    SBC: PROLOCOR INC.            Topic: NHLBI

    ABSTRACT The American Heart Association estimates that, in 2022, about 720,000 Americans will have a first coronary event and 335,000 will have a recurrent event, of which, approximately 87% are ischemic (thrombotic). Anti- thrombotic therapy reduces the risk of recurrent ischemic events at the cost of a greater incidence of bleeding complications. Patients at low thrombotic/ischemic risk should b ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Validation of Point-of-Care Breath Test for Pulmonary TB

    SBC: MENSSANA RESEARCH INC            Topic: NIAID

    DESCRIPTION provided by applicant The problem Active pulmonary tuberculosis TB is a leading cause of death from infectious disease throughout the world Two billion people one third of the worldandapos s population are infected with Mycobacterium tuberculosis and million died from the disease in Sputum microscopy and culture remains the mainstay of laboratory diagnosis accompani ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. VALIDATION OF PROSTATE CANCER ONCOGENES

    SBC: Eikos, Inc.            Topic: N/A

    We propose the creation of a comprehensive tissue microarray consisting of all pathologic stages of adenocarcinoma of the prostate as a tool for testing promising cellular markers - genes and proteins that will serve as an aid to researchers in validating the potential usefulness of any given marker. We propose to create this tissue microarray and test its usefulness by observing the differential ...

    SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government